Vet Clin Path Journal http://vetclinpathjournal.org/ Sat, 09 Oct 2021 04:30:31 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://vetclinpathjournal.org/wp-content/uploads/2021/05/cropped-icon-32x32.png Vet Clin Path Journal http://vetclinpathjournal.org/ 32 32 2021 Veterinary Chemical Analyzer Market Survey by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2028 https://vetclinpathjournal.org/2021-veterinary-chemical-analyzer-market-survey-by-manufacturers-share-growth-trends-types-and-applications-forecast-to-2028/ https://vetclinpathjournal.org/2021-veterinary-chemical-analyzer-market-survey-by-manufacturers-share-growth-trends-types-and-applications-forecast-to-2028/#respond Sat, 09 Oct 2021 03:02:58 +0000 https://vetclinpathjournal.org/2021-veterinary-chemical-analyzer-market-survey-by-manufacturers-share-growth-trends-types-and-applications-forecast-to-2028/

Limited time offer until October 20 only: Don’t miss this opportunity.

Los Angeles, California, United States: The study covers all aspects of Veterinary Chemical Analyzers including the economic assessment and contributions from different industries, market size forecasts for key segments, emerging market models, market dynamics and expense. final logistics.

Veterinary Chemical Analyzers Market is expected to grow at a CAGR of xx% during the forecast period 2021-2028

Request an exclusive “FREE REPORT EXAMPLE” from the veterinary chemical analyzer market: https://www.esticastresearch.com/report/veterinary-chemical-analyzers-market/#request-for-sample

Veterinary chemical analyzers, segmentation and region:

  • According to the Global Opportunity Analysis and Industry Forecast, 2021-2028, the global demand for the market is expected to reach $ xx, xx billion. The base year for the study is 2020, with projections ranging from 2021 to 2028. The study covers all aspects of global economies, including economic assessments.
  • The research report study covers all aspects of the Veterinary Chemical Analyzers markets including the economic assessment and contributions from different industries, market size forecasts for key segments, market dynamics, models emerging market and final logistics expenses.
  • This market research report has been generated to provide a detailed market overview and guide to COVID-19, current markets, models, actions, drivers, gradual growth, and key companies. It was. The research report provides market-wide data to key vendors, traders, distributors and resellers in the current context of COVID-19 pandemic.

Competitive landscape

A competitive landscape for veterinary chemical analyzers is given in the study. To differentiate business attributes, large companies operating in the industry have been identified and profiled.

The competitive landscape of the market provides details by the participants. These details include financial data, overviews, revenue generated, market potentials, etc. in research and development, new market initiatives and global presence. Manufacturing sites and facilities, company strengths and manufacturing capabilities.

For complete information on the report with TOC, visit here: https://www.esticastresearch.com/report/veterinary-chemical-analyzers-market

Regional development:

The overview of the report draws on a variety of primary and secondary data sources. North America, Europe, Middle East & Africa, and Asia Pacific by region are expected to dominate veterinary chemical analyzers during the forecast period. These regions have been the market leaders for all segments in terms of technological developments and increased research and development activities in the region.

In addition, government policies have been favorable to the growth of the market in these regions. North America and Europe have an established market for product innovations and early adaptations. This is expected to stimulate demand for veterinary chemical analyzers.

Major Highlights:

  • Conceptual analysis of research segmented by growth, Segmentation
  • The report offers a comprehensive analysis of future market trends to understand investment opportunities.
  • Dynamics such as drivers, restraints, opportunities, other market trends and challenges
  • Clear research and precise analysis to change competitive dynamics
  • Key market trends in several business segments, countries and regions

It is expected to pilot veterinary chemical analyzers during the forecast period. This research report covers the outlook and advancement of the market for the near future.

The report overview includes that the researchers shed light on key strengths, weaknesses, opportunities, challenges and threats impacting the growth of the markets. The feasibility of the new report is also measured in this research report.

Interesting.? Request a sample report: https://www.esticastresearch.com/report/veterinary-chemical-analyzers-market/#request-for-sample

The study will include the overall analysis of the Veterinary Chemical Analyzers market and is segmented

By target audience

• Manufacturers and distributors of veterinary chemistry analyzers
• Veterinary research and development (R&D) companies
• Government associations
• Reference veterinary laboratories
• Market research and consulting firms
• Venture capitalists and investors

By product Instruments

• Chemistry analyzers
• Urine analyzers
• Glucometers
• Blood gas and electrolyte analyzers

By consumables

• Preloaded multiple reagent panels
• Preloaded single slide reagent panels
• Reagent strips
• Reagents

By animal type

• Pets
•Livestock

By application

• Blood chemistry analysis
• Urine analysis
• Blood glucose monitoring
• Analysis of blood gases and electrolytes

Some of the major players featured in the report are

DEXX Laboratories, Inc. (United States)
Heska Corporation (United States)
Abaxis, Inc. (US)
Randox Laboratories Ltd. (UK)
ARKRAY, Inc. (Japan)
Alfa Wassermann Inc. (United States)
DiaSys diagnostic systems
Eurolyser Diagnostica GmbH (Austria)
United States, LLC (United States)
Chengdu Seamaty Technology Co., Ltd. (China)

Make a request before you buy: https://www.esticastresearch.com/report/veterinary-chemical-analyzers-market/#inquiry-before-buying

Customization of Veterinary Chemical Analyzers Market report

We also provide customization of reports according to specific client requirements. Personalization can also be based on national or regional levels. Connect with our sales and research team at ash@esticastresearch.com and + 1-213-262-0704 and get your job done in just a few

Contact us:

Mr. Ashish Gedamkar
Business Sales Specialist
Esticast Search
United States: + 1-213-262-0704
APAC: + 91-959-503-5024
Email: ash@esticastresearch.com
Visit our website: www.esticastresearch.com

]]>
https://vetclinpathjournal.org/2021-veterinary-chemical-analyzer-market-survey-by-manufacturers-share-growth-trends-types-and-applications-forecast-to-2028/feed/ 0
Early Release – Co-Infection with 4 Species of Mycobacteria Identified by Using Next-Generation Sequencing – Volume 27, Number 11 — November 2021 – Emerging Infectious Diseases journal https://vetclinpathjournal.org/early-release-co-infection-with-4-species-of-mycobacteria-identified-by-using-next-generation-sequencing-volume-27-number-11-november-2021-emerging-infectious-diseases-journal/ https://vetclinpathjournal.org/early-release-co-infection-with-4-species-of-mycobacteria-identified-by-using-next-generation-sequencing-volume-27-number-11-november-2021-emerging-infectious-diseases-journal/#respond Fri, 08 Oct 2021 21:03:00 +0000 https://vetclinpathjournal.org/early-release-co-infection-with-4-species-of-mycobacteria-identified-by-using-next-generation-sequencing-volume-27-number-11-november-2021-emerging-infectious-diseases-journal/ Disclaimer: Pre-published articles are not considered final versions. Any changes will be reflected in the online version the month the article is officially published.

Author affiliations: University of California, Los Angeles, California, United States (L. Wang, E. Vikram, A. Zou, G. Cheng); New York-Presbyterian Queens Hospital, Flushing, New York, USA (D. Liu, L. Yung, GD Rodriguez, N. Prasad, S. Segal-Maurer, V. Singh, WH Rodgers); Weil Cornell Medical College, New York (WH Rodgers)

Mycobacteria are major human pathogens; ≈13 million people in the United States live with Mycobacterium tuberculosis complex (MTBC) and the incidence of non-tuberculous mycobacterial lung disease (NTM) is increasing worldwide. The challenges of managing MTBC and M. avium complex coinfections (CAM) are well described, including the risk of misinterpreted Xpert RIF (rifampin) results (1,2). MTBC and Mr. abscess co-infection has only been described in case reports (3,4). We describe the co-infection with 4 species of mycobacteria.

In July 2019, an 82-year-old Asian woman was hospitalized in Flushing, New York, United States, with a persistent fever associated with worsening weakness. A CT scan of her chest showed almost complete left upper lobe atelectasis, hyperinflation in other areas, and a small left pleural effusion. Scattered bud tree-shaped nodular opacities and pulmonary granulomas were present in all lungs, and discontinuity of the left upper lobe bronchus was noted. Cultures of blood, urine, stool and respiratory samples gave negative results for non-mycobacteria.

In a sputum sample collected for routine mycobacterial testing, fluorochrome staining showed rare acid-fast bacilli, and MTBC was detected using Xpert MTB / RIF (Cepheid, https: //www.cepheid. com). We then inoculated sputum at a Lowenstein-Jensen Gruft slope, incubated it at 37 ° C, and inoculated VersaTREK Myco bottles containing Middlebrook 7H9 broth modified with sponges (Thermo Fisher, https://www.thermofisher.com ) and incubated them at 35 ° C. No isolates were recovered from the Lowenstein-Jensen Gruft slope. Only MAC was detected by AccuProbe (Hologic, https://www.hologic.com) in the positive Kinyoun culture of Myco bottles. A week later, another sputum sample with growth positive for Kinyoun from the Myco vials was negative for MAC, MTBC, Mr. gordonae, and Mr. kansasi. Mr. abscess was identified on the Lowenstein-Jensen Gruft slope.

Given the sensitivity limit and narrow species coverage of AccuProbe and the difficulty of identifying mycobacteria by culture and due to growth interferences between different mycobacteria, we performed next-generation sequencing (NGS ) using Hiseq3000 (Illumina, https: //www.illumina. com) on the first sputum culture supernatant. NGS generated ≈ 175 million reads, each with a quality score> 35. We checked the NGS data for quality control using FastQC (Galaxy, https://usegalaxy.org). All stages and programs used Galaxy’s data processing pipeline, an open-source web-based platform for data-intensive biomedical research. Each identified reading had a quality control score of 39.4 and an average guanine-cytosine content of 68%. Only 0.69% of the bases gave no results and were not identifiable. We performed De Novo classification using De Novo Assembly Unicycler, Quast QC and Kraken Classification (Galaxy) and generated coverage and depth data using BWA Aligner and SAMtools Depth (Galaxy). We aligned the reads, visualized on the bacteria’s reference genomes using Bowtie2 (Galaxy) and converted to BED (Browser Extensible Data) files followed by Bedtools Merge, Multicov (https://bedtools.readthedocs.io) .

Figure

Figure. Genomic coverage and depth map of 4 Mycobacteriumstrains identified using next generation sequencing on isolates from a female in New York, New York, USA. The readings were aligned …

The genome visualization pipeline confirmed 4 genomic traces of Mycobacterium strains (Figure): Mr. yongonense strain 05-1390 (GenBank accession number NC_021715.1), M. tuberculosis strain FDAARGOS_757 (GenBank accession number CP054013.1), Mycobacterium sp. MOTT36Y (GenBank accession number NC_017904.1), and M. abscess ATCC 19977 (GenBank accession number CU458896.1). Mr. yongonense was identified with a genomic coverage of 88.73% (4.9 Mb mapped on 5.5 Mb genome) and a read depth of 1224 ×. M. tuberculosis was identified with a genomic coverage of 99.99% (4.4 Mb mapped onto 4.4 Mb genome) and a read depth of 63 ×. Mycobacterium sp. was identified with a genome coverage of 94.41% (5.3 Mb mapped from the 5.6 Mb genome) and a read depth of 1210 ×. Mr. abscess was identified with a genome coverage of only 2.75% (0.14 Mb mapped from the 5.1 Mb genome) and a read depth of 8 × (table). The mycobacteria identified by NGS were verified by various mycobacteria tests.

We obtained the consensus sequence for 4 strains of bacteria using MEGAHIT (Galaxy) and generated a BLAST tree (https://blast.ncbi.nlm.nih.gov/Blast.cgi) based on minimal evolution at the level of the species using >15 kbp of each sequence. Assembly on MTBC sequencing data gave a total consensus sequence of 4,376,826 bp and 78,208 single nucleotide polymorphism sites (1.79%). Analysis by BLAST and Mykrobe (https://www.mykrobe.com) revealed that the MTBC isolate belongs to the 2.2 subline.

The patient received RIPE treatment (rifampin, isoniazid, pyrazinamide and ethambutol), as well as amikacin, tigecycline and azithromycin. At 6 months, the RIPE treatment was finished. At 9 months, the sputum culture was negative. The patient continues to take amikacin, tigecycline and azithromycin on an outpatient basis with close monitoring.

Identification of co-infection with mycobacteria is necessary for diagnosis and treatment (5). Treatment regimens and duration remain species specific due to unique resistance mechanisms. To achieve the greatest potential for success while minimizing toxicities, early empiric treatment should take into account the clinical features of MTBC and NTM co-infection and strain identification.

Our report highlights the value of NGS in identifying multiple mycobacterial co-infections in populations with high susceptibility and prevalence of MTB and NCD (i.e. immigrants, immunocompromised patients and international travelers) . NGS can trace the geographic origin of the Mycobacterium stump. These characteristics, combined with a patient’s epidemiological exposure and travel history, could elucidate the potential time and place of infection acquisition. NGS could also be used to identify drug resistance genes to guide targeted therapy.

Dr Wang is a postdoctoral researcher in the Department of Microbiology, Immunology and Molecular Genetics at the University of California, Los Angeles. His research focuses on immunology, virology and molecular diagnostics. Dr Liu is the Director of the Laboratory of Microbiology, Immunology and Molecular Diagnostics, Department of Pathology and Clinical Laboratories, New York-Presbyterian Queens Hospital. His research focuses on the development of rapid molecular tests for the diagnosis of pathogens.

Mountain peak

The conclusions, findings, and opinions expressed by the authors contributing to this review do not necessarily reflect the official position of the United States Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or institutions affiliated with the. authors. . Use of trade names is for identification purposes only and does not imply endorsement of any of the groups mentioned above.

Source link

]]>
https://vetclinpathjournal.org/early-release-co-infection-with-4-species-of-mycobacteria-identified-by-using-next-generation-sequencing-volume-27-number-11-november-2021-emerging-infectious-diseases-journal/feed/ 0
Biden is the first president to mark Indigenous Peoples Day https://vetclinpathjournal.org/biden-is-the-first-president-to-mark-indigenous-peoples-day/ https://vetclinpathjournal.org/biden-is-the-first-president-to-mark-indigenous-peoples-day/#respond Fri, 08 Oct 2021 15:37:00 +0000 https://vetclinpathjournal.org/biden-is-the-first-president-to-mark-indigenous-peoples-day/

WASHINGTON (AP) – President Joe Biden issued the first-ever presidential proclamation of Indigenous Peoples Day on Friday, providing the most significant impetus to date in efforts to refocus the federal holiday celebrating Christopher Columbus towards a peoples appreciation indigenous.

Biden also issued a Columbus Day proclamation on Monday, October 11, which is established by Congress.

“For generations, federal policies have systematically sought to assimilate and displace Indigenous peoples and eradicate Indigenous cultures,” Biden wrote in the proclamation of Indigenous Peoples Day. “Today, we recognize the resilience and strength of Indigenous peoples and the immeasurable positive impact they have had on all aspects of American society.”

In a separate Columbus Day proclamation, Biden praised the role of Italian Americans in American society, but also referred to the violence and damage that Columbus and other explorers of the day wrought on the Americas. .

“Today we also recognize the painful history of the wrongs and atrocities that many European explorers inflicted on tribal nations and indigenous communities,” Biden wrote. “It is a measure of our greatness as a nation that we do not seek to bury these shameful episodes from our past – that we face them honestly, that we bring them to light and do all we can to remedy them. “

It is a break with President Donald Trump’s ardent defense of “fearless heroes” like Columbus in his proclamation of the holiday in 2020.

“Sadly, in recent years radical activists have sought to undermine the legacy of Christopher Columbus,” Trump said at the time. “These extremists seek to replace discussion of his vast contributions with discussions of his failures, his discoveries with atrocities, and his accomplishments with transgressions. “

Copyright 2021 The Associated Press. All rights reserved.

Source link

]]>
https://vetclinpathjournal.org/biden-is-the-first-president-to-mark-indigenous-peoples-day/feed/ 0
Global Clinical Trial Kits Market (2021-2028) https://vetclinpathjournal.org/global-clinical-trial-kits-market-2021-2028/ https://vetclinpathjournal.org/global-clinical-trial-kits-market-2021-2028/#respond Fri, 08 Oct 2021 08:33:00 +0000 https://vetclinpathjournal.org/global-clinical-trial-kits-market-2021-2028/

Dublin, October 08, 2021 (GLOBE NEWSWIRE) – The Clinical Trial Kits Market Size, Share and Trend Analysis Report by Department (Kit Solutions, Logistics), by Phase (Phase I, Phase II, Phase III, Phase IV), by Region and segment forecast, 2021-2028 “ report was added to ResearchAndMarkets.com offer.

The global clinical trial kits market size is expected to reach $ 2.5 billion by 2028, according to a new report from the publisher. The market is expected to grow at a CAGR of 8.5% from 2021 to 2028. Factors driving the market expansion include globalization of clinical trials, increasing demand for remote services, and increasing complexity of trials. clinics.

Remote clinical trial services are becoming increasingly essential in terms of patient retention, satisfaction and safety. To enhance their capabilities, pharmaceutical companies have established a relationship with global logistics partners to provide direct services to patients. These services provide participants with the flexibility and convenience of participating in trials while staying at home.

The COVID-19 pandemic has affected the market, which has slowed down the testing process. The COVID-19 pandemic is rapidly spurring advancements in medical practices that allow people to remotely connect to the healthcare system. This effort to examine patients at home has sparked interest in home sample collection and testing. These services are convenient and minimize the potential exposure to SARS-CoV-2.

Companies have started offering digital direct testing services to consumers. Other aspects of the testing process, from ordering tests to collecting samples, are already making their way into patient homes. In addition, regulatory authorities instantly gave sponsors directions to address issues that arose during ongoing clinical studies. Changes such as the use of telemedicine, the elimination of non-essential laboratory visits and assessments, as well as diagnostic testing and sample collection, have allowed many studies to continue while ensuring the patient safety during the pandemic.

Highlights of the Clinical Trial Kits Market Report

  • The logistics segment dominated the market and accounted for the largest revenue share of 54.9% in 2020. This is due to the increasing demand for services to simplify the logistics process in clinical trials.

  • Phase III segment dominated the market and accounted for the largest revenue share of 53.4% ​​in 2020 as phase III trials require large numbers of participants

  • North America dominated the market in 2020 due to favorable government support and the existence of a large number of companies offering innovative services in the United States.

  • In Asia-Pacific, the market is expected to experience the highest CAGR of 9.9% during the forecast period as the region keeps growing in terms of clinical trials due to the large population and technology. in development.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Kits Market: Variables, Trends and Scope
3.1 Market Lineage Outlook
3.1.1 Parents’ Market Outlook
3.1.2 Auxiliary Market Outlook
3.2 Mapping of penetration and growth prospects
3.3 Market dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Globalization of clinical trials
3.3.1.2 Growing demand for remote services
3.3.1.3 Growing complexity of clinical trials
3.3.2 Analysis of market restrictions
3.3.2.1 Different regulations depending on the country
3.4 Analysis Tools of the Clinical Trial Kits Market
3.4.1 Porter’s five forces analysis
3.4.2 PESTEL analysis
3.4.3 Major transactions and strategic alliances
3.4.3.1 Acquisition
3.4.3.2 Partnerships
3.4.3.3 Enlargement
3.4.3.4 Product launch
3.4.3.5 Collaboration
3.5 Clinical Trial Kits Market: Total Addressable Market (TAM) Analysis
3.5.1 Market Overview

Chapter 4 Impact of Covid-19
4.1 Impact of COVID-19 on the market
4.2 Impact of COVID-19 on logistics
4.3 Impact of the COVID-19 pandemic on clinical trial activity
4.3.1 Barriers to Clinical Trials
4.3.2 Discontinued clinical trials
4.3.2.1 Companies with Phase I trial interruption
4.3.2.2 Companies with Phase 2 trial interruption
4.3.2.3 Companies with Phase 3 trial interruption

Chapter 5 Clinical Trial Kits Market: Service Segment Analysis
5.1 Clinical trial kits: market share analysis, 2020 and 2028
5.2 Assembly solutions
5.2.1 Kitting Solutions Market, 2016-2028 (USD Million)
5.2.2 Drug kits
5.2.2.1 Drug Kits Market, 2016-2028 (USD Million)
5.2.3 Sample collection kits
5.2.3.1 Sample Collection Kits Market, 2016-2028 (USD Million)
5.3 Logistics
5.3.1 Logistics Market, 2016-2028 (USD Million)
5.3.2 Transport
5.3.2.1 Transportation Market, 2016-2028 (USD Million)
5.3.3 Warehousing and storage
5.3.3.1 Warehousing and Storage Market, 2016-2028 (USD Million)
5.3.4 Others
5.3.4.1 Other markets, 2016 – 2028 (USD million)

Chapter 6 Clinical Trial Kits Market: Phase Segment Analysis
6.1 Clinical Trial Kits: Market Share Analysis, 2020 and 2028
6.2 Phase I
6.2.1 Phase I Market, 2016-2028 (USD Million)
6.3 Phase II
6.3.1 Phase II Market, 2016 – 2028 (USD Million)
6.4 Phase III
6.4.1 Phase III Market, 2016-2028 (USD Million)
6.5 Phase IV
6.5.1 Phase IV Market, 2016-2028 (USD Million)

Chapter 7 Clinical Trial Kits Market: Regional Analysis

Chapter 8 Competitive Landscape
8.1 Company profiles
8.1.1 Brooks Life Sciences
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Benchmarking of services
8.1.1.4 Strategic initiatives
8.1.2 Q2 solutions
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Benchmarking of services
8.1.2.4 Strategic initiatives
8.1.3 Patheon (Thermo Fisher Scientific Inc)
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 ServicebBenchmarking
8.1.4 Labcorp Drug Development
8.1.4.1 Company overview
8.1.4.2 financial performance
8.1.4.3 Benchmarking of services
8.1.4.4 Strategic initiatives
8.1.5 Charles River Laboratories
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Benchmarking of services
8.1.6 LAbConnect
8.1.6.1 Company overview
8.1.6.2 Benchmarking of services
8.1.6.3 Strategic initiatives
8.1.7 Almac Group
8.1.7.1 Company overview
8.1.7.2 Benchmarking of services
8.1.7.3 Strategic initiatives
8.1.8 Precision Medicine Group
8.1.8.1 Company overview
8.1.8.2 Benchmarking of services
8.1.8.3 Strategic initiatives
8.1.9 Cerba search
8.1.9.1 Company overview
8.1.9.2 Benchmarking of services
8.1.10 Alpha Laboratories
8.1.10.1 Company overview
8.1.10.2 Benchmarking of services
8.1.11 Marking a UPS Company
8.1.11.1 Company overview
8.1.11.2 Benchmarking of services
8.1.11.3 Strategic initiatives
8.1.12 Clinogen
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Benchmarking of services
8.1.12.4 Strategic initiatives

For more information on this report, visit https://www.researchandmarkets.com/r/lbz1ty

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Source link

]]>
https://vetclinpathjournal.org/global-clinical-trial-kits-market-2021-2028/feed/ 0
BetterVet Mobile Vet Care Continues Coast-to-Coast Expansion with Launches in Seattle and San Francisco https://vetclinpathjournal.org/bettervet-mobile-vet-care-continues-coast-to-coast-expansion-with-launches-in-seattle-and-san-francisco/ https://vetclinpathjournal.org/bettervet-mobile-vet-care-continues-coast-to-coast-expansion-with-launches-in-seattle-and-san-francisco/#respond Thu, 07 Oct 2021 13:00:00 +0000 https://vetclinpathjournal.org/bettervet-mobile-vet-care-continues-coast-to-coast-expansion-with-launches-in-seattle-and-san-francisco/

Boston-based veterinary startup crosses country and lands on the West Coast

Posted: October 7, 2021 at 7:00 a.m. MDT|Update: 31 minutes ago

BOSTON, October 7, 2021 / PRNewswire / – Mobile veterinary startup, BetterVet, today announced its latest launch in new markets, with the addition of Dr. Calvin Lum in San Francisco and Dr Hanna Ekström in Seattle.

BetterVet Logo (PRNewsfoto / BetterVet)

Founded by an industry pioneer Bruce herzfelder, with the former president of AVMA, Dr. Jean de Jong, BetterVet is the first family veterinary care provider of its kind providing comprehensive mobile veterinary care across the country. At its core, BetterVet provides a high vet experience by meeting the animal from the comfort of their own home while saving pet parents from having to take their anxious pets to the vet. Additionally, they use a mobile app and website to provide streamlined appointment scheduling, virtual vet visits and telehealth communications, access to medical records and certificates, and an online pharmacy.

BetterVet’s modern, mobile approach to veterinary medicine promotes a better veterinary care experience for pets and pet parents. Every BetterVet veterinarian is Without fear® certified as a badge of their commitment to minimizing the anxiety and stress of furry family members.

With the primary goal of providing the highest level of veterinary care to his patients, Dr. Calvin Lum is looking forward to joining the BetterVet family and working alongside an impressive and diverse team. Dr Lum says, “As the owner of my own mobile practice, San Francisco Veterinary Housecalls, since 2008, I have worked on my own for the past 13 years. I look forward to merging my practice with BetterVet. The added support of a veterinary nurse, a committed and involved team of professionals, and state-of-the-art veterinary medicine and supplies will allow me to better serve my patients in the long term as well as support new families. With the support of BetterVet, I can focus my time being a home vet and turning my practice into the dream I always wanted. “

Dr Hanna Ekström began practicing in 1992, just after graduating with honors from Cornell College veterinary medicine. Dr. Ekström first worked with all pets before focusing on small animal medicine and launching her own mobile practice called At Home Vet. After selling At Home Vet in 2017, she launched Gentle Home Vet and a “sister” practice known as Angel Wings Vet, which focuses solely on palliative and end-of-life care. Dr Ekström is excited to join the BetterVet team and says she “couldn’t be more excited to join the BetterVet team” and is “looking forward to bringing an exceptional and compassionate veterinary experience to her clients. alongside a team of competent and supportive service providers. “

BetterVet is excited to continue its national expansion on the West Coast with the addition of Dr. Calvin Lum and Dr Hanna Ekström. To recognize this step, BetterVet will offer customers a free initial video consultation if they are booked between October 14, 2021 and November 14, 2021. In addition, new customers in the San Francisco and Seattle areas can use promo code SF95 Where SEATTLE95 receive a $ 95 delivery by appointment at home. To make an appointment, download BetterVet’s handy mobile app or visit BetterVet appointment page Going through bestvet.com.

About BetterVet
Founded in July 2020, BetterVet is a truly mobile veterinary service providing a simple and hassle-free healthcare experience for pets, pet parents, and veterinary care providers. From telemedicine to home visits, BetterVet provides all the expert veterinary services you would find in a physical practice, but in the comfort of your own home, free from stress, anxiety and inconvenience. BetterVet is currently available in the Greater Boston, Philadelphia cream, Pittsburgh, Denver, Austin, palm beach and Broward and will soon launch in other cities in the United States. To learn more about BetterVet and get better veterinary care in just a few clicks, visit www.bettervet.com, or download the app on any mobile device.

Related links
https://www.bettervet.com

View original content to download multimedia:

SOURCE BetterVet

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

]]>
https://vetclinpathjournal.org/bettervet-mobile-vet-care-continues-coast-to-coast-expansion-with-launches-in-seattle-and-san-francisco/feed/ 0
Top tech news from AACC 2021 https://vetclinpathjournal.org/top-tech-news-from-aacc-2021/ https://vetclinpathjournal.org/top-tech-news-from-aacc-2021/#respond Thu, 07 Oct 2021 11:11:49 +0000 https://vetclinpathjournal.org/top-tech-news-from-aacc-2021/

We’ve rounded up the latest clinical news and technological advancements that have made waves at this year’s conference

The American Association for Clinical Chemistry (AACC) 2021 Annual Scientific Meeting and Clinical Laboratory Expo was held September 26-30 in Atlanta, Georgia. This year’s conference was held in person and was also available virtually for those who were unable to travel due to the pandemic.

The event had over 400 exhibitors, with over 50 expert speakers and a product showcase showcasing the latest diagnostic technologies, SARS-CoV-2 testing, mHealth, automation and point-of-service solutions. Speakers at the event covered topics related to emerging technologies in laboratory medicine, the burden of infectious diseases, microsystems engineering, emergency medicine and much more.

This year’s conference attendees were also invited to participate in the COVID-19 Immunity Study, launched by the AACC. The study aims to study the longevity of the vaccine and to examine the use of serological tests to measure lasting immunity in a large cohort.

In this news summary, discover the best technologies and research on the news shared at the show, click on the headlines to find out more.

The AACC 2022 Annual Scientific Meeting and Clinical Laboratory Exhibition will be held in Chicago from July 24-28, 2022.

Want the latest science news delivered straight to your inbox? Become a Free SelectScience Member Today >>

Source link

]]>
https://vetclinpathjournal.org/top-tech-news-from-aacc-2021/feed/ 0
Denali Therapeutics Announces Positive Clinical Results and Regulatory Advances for Developmental Programs in Amyotrophic Lateral Sclerosis (ALS) | Small molecules https://vetclinpathjournal.org/denali-therapeutics-announces-positive-clinical-results-and-regulatory-advances-for-developmental-programs-in-amyotrophic-lateral-sclerosis-als-small-molecules/ https://vetclinpathjournal.org/denali-therapeutics-announces-positive-clinical-results-and-regulatory-advances-for-developmental-programs-in-amyotrophic-lateral-sclerosis-als-small-molecules/#respond Thu, 07 Oct 2021 09:19:38 +0000 https://vetclinpathjournal.org/denali-therapeutics-announces-positive-clinical-results-and-regulatory-advances-for-developmental-programs-in-amyotrophic-lateral-sclerosis-als-small-molecules/

Denali Therapeutics Announces Positive Clinical Results and Regulatory Advances for Developmental Programs in Amyotrophic Lateral Sclerosis (ALS)

  • The eIF2B DNL343 activator achieved safety and biomarker objectives in a phase 1 study in healthy volunteers; a phase 1b study started in people with ALS in the third trimester of 2021
  • US Food and Drug Administration (FDA) Fast Track designation for SAR443820 / DNL788, an inhibitor of RIPK1, for the treatment of ALS; Sanofi to launch phase 2 study in people with ALS in the first quarter of 2022

SOUTH SAN FRANCISCO, CA, USA I October 06, 2021 IDenali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates designed to cross the blood-brain barrier (BBB) ​​for neurodegenerative diseases, today announced positive clinical results for Phase 1 and Regulatory advancements for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis (ALS) at the 2021 Northeast ALS Annual Meeting (NEALS) to be held virtually October 6-7.

“Effective treatment options are a critical unmet medical need for people living with ALS,” said Carole Ho, MD, medical director of Denali. “DNL343 and SAR443820 are designed to modulate distinct biological pathways involved in ALS, including the integrated stress response and inflammation, respectively. We are delighted that the data generated in the preclinical and in the Phase 1 studies support the clinical study of both molecules as potential treatments for people with ALS.

“We are very encouraged by the initial results of the Phase 1 study of SAR443820 for the treatment of ALS,” said Nazem Atassi, MD, Global Head of Early Neurodevelopment at Sanofi. “ALS is a devastating disease for patients and their families, with no cure available or effective treatment to slow its progression. We look forward to launching the Phase 2 HIMALAYA trial in adults with ALS in early 2022 and reaching our ultimate goal of helping people living with ALS.

Highlights of clinical and preclinical data of eIF2B DNL343 activator presented to NEALS

Denali reported positive results from a phase 1 study in healthy volunteers (n = 95) in which the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple escalating doses of DNL343 were evaluated. Results demonstrated that DNL343 was generally well tolerated up to 14 days of administration, with robust distribution in the central nervous system (CNS) and predictable dose-related increases in DNL343 exposure with a pharmacokinetic profile. supporting a single daily dose. Biomarker evaluations have also been performed in relation to the integrated cellular stress response (ISR). ISR is a biological pathway implicated in ALS and other diseases. After healthy volunteers were treated with DNL343, samples of their blood cells were put under stress ex vivo, and significant changes in ISR biomarkers were observed, confirming pathway engagement.

Denali also presented preclinical data in a mouse model of endangered white matter disease (VWM), a genetic and progressive disorder that causes severe neurological symptoms after exposure to certain stressors. EIF2B activity is reduced in the VMW disease model leading to chronic activation of ISR, making it a relevant model to demonstrate target engagement and modulation of ISR by DNL343. After treatment with DNL343, body weight and motor function were normalized in these mice. In addition, the expression of the ISR gene and the levels of stress response proteins were reduced both in peripheral tissues and in the brain. A similar PK / PD relationship was observed in mice and humans, supporting dose selection of DNL343 in the ongoing Phase 1b study in participants with ALS.

The Phase 1b study (NCT05006352) is a 28-day, multicentre, randomized, placebo-controlled, double-blind study followed by an 18-month open-label extension designed to assess safety, pharmacokinetics and PD of DNL343 in approximately 30 participants with ALS. Dosage in this study began in the third quarter of 2021.

Highlights from RIPK1 Inhibitor SAR443820 Clinical Trial Design Presentation to NEALS and Fast Track Designation

Denali’s partner Sanofi presented plans for a Phase 2 study of the RIPK1 inhibitor SAR443820 in participants with ALS based on positive results from a Phase 1 study in healthy volunteers. In this study, robust target engagement was demonstrated at generally well tolerated doses. The phase 2 study, named HIMALAYA, is a multicenter, randomized, double-blind, placebo-controlled study followed by a long-term open-label extension to evaluate the efficacy and safety of SAR443820 in adult participants with ALS. This phase 2 study is expected to begin in the first quarter of 2022.

The US FDA has granted Fast Track designation to SAR443820 for the treatment of ALS. Fast Track is an FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and meet an unmet medical need. The Fast Track designation may allow early and frequent communication with the FDA regarding the development of SAR443820 for the treatment of ALS. This designation also allows for continuous review of the marketing application.

About the eIF2B DNL343 Activator

Modulating eIF2B activity with DNL343 is a novel and targeted experimental approach with first-order potential for the treatment of ALS. eIF2B is an intracellular protein complex that regulates protein synthesis and is necessary for neuronal health and function. When neurons are under stress, as occurs in ALS, eIF2B activity is suppressed. This leads to impaired protein synthesis and results in the formation of “stress granules”, which are considered to be a precursor to the aggregation of TDP-43, a pathology characteristic of ALS. DNL343 is designed to activate eIF2B and thereby restore protein synthesis, disperse TDP-43 aggregates and improve neuronal survival. DNL343 is an investigational drug and has not been approved by any regulatory authority for commercial use.

About RIPK1 SAR443820 / DNL788 Inhibitor

SAR443820 / DNL788 is a novel CNS-penetrating small molecule inhibitor of RIPK1, a critical signaling mediator of necroptotic cell death, cytokine release, and inflammatory pathways. Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors. This includes CNS penetrating molecules such as SAR443820 / DNL788, which was evaluated in a Phase 1 study in healthy volunteers, with potential development for neurological indications such as ALS, multiple sclerosis (MS) and MS. Alzheimer’s disease (AD). Sanofi is leading the Phase 1 and Phase 2 development of SAR443820 / DNL788 for ALS and MS and leading the co-development of SAR443820 / DNL788 with Denali in Phase 3 clinical trials for ALS, AD and MS. SAR443820 / DNL788 is an investigational drug which has not been approved by any regulatory authority for commercial use.

About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates designed to cross the blood brain barrier (BBB) ​​for neurodegenerative diseases. Denali pursues new treatments by rigorously evaluating genetically validated targets, designing delivery through BBB, and guiding development with biomarkers that demonstrate target and pathway engagement. Denali is based in southern San Francisco. For more information, please visit www.denalitherapeutics.com.

THE SOURCE: Therapeutic Denali

Source link

]]>
https://vetclinpathjournal.org/denali-therapeutics-announces-positive-clinical-results-and-regulatory-advances-for-developmental-programs-in-amyotrophic-lateral-sclerosis-als-small-molecules/feed/ 0
ABIONYX Pharma announces positive preclinical results in a uveitis model and launches the strategic development of the first class of biomedicines in ophthalmology based on its bio-HDL https://vetclinpathjournal.org/abionyx-pharma-announces-positive-preclinical-results-in-a-uveitis-model-and-launches-the-strategic-development-of-the-first-class-of-biomedicines-in-ophthalmology-based-on-its-bio-hdl/ https://vetclinpathjournal.org/abionyx-pharma-announces-positive-preclinical-results-in-a-uveitis-model-and-launches-the-strategic-development-of-the-first-class-of-biomedicines-in-ophthalmology-based-on-its-bio-hdl/#respond Thu, 07 Oct 2021 06:57:27 +0000 https://vetclinpathjournal.org/abionyx-pharma-announces-positive-preclinical-results-in-a-uveitis-model-and-launches-the-strategic-development-of-the-first-class-of-biomedicines-in-ophthalmology-based-on-its-bio-hdl/

TOULOUSE, France & LAKELAND, Michigan, October 07, 2021– (BUSINESS WIRE) – Regulatory news:

ABIONYX Pharma (Paris: ABNX) (FR0012616852 – ABNX – PEA PME eligible), a new generation biotechnology company dedicated to the discovery and development of innovative therapies, announces today, after having already obtained an orphan drug designation for CER-001 in the treatment of LCAT deficiency, positive preclinical results in ophthalmology and the launch of a strategic development of the first class of biomedicines of its bio-HDL for the treatment of ocular pathologies.

Positive preclinical results in a uveitis model

Following the positive clinical results which included the disappearance of visual blurring linked to corneal lipid deposits in a patient suffering from an LCAT deficiency, treated under a Temporary Authorization for Use, and the marked improvement in the patient’s visual functions which was still observed after 1 year of follow-up (initial results published exclusively in the scientific journal “Annals of Internal Medicine; follow-up information on file), ABIONYX Pharma carried out preclinical studies in ophthalmology to determine the ocular tolerance of its bio-HDL and the potential spectrum of efficacy in new indications.

Bio-HDL has been shown to be completely safe and very well tolerated on the ocular surface and inside the eye, regardless of the route of administration in a preclinical study, either by intravenous injection, by application of drops on the surface of the eye or by injection inside the eye itself (into the vitreous).

Additionally, bio-HDL has been tested in a proof of concept efficacy study using a recognized and validated preclinical model of uveitis. In this model of endotoxin-induced uveitis (EIU), the uveitis was triggered by a dose of lipopolysaccharide (LPS) injected into the vitreous. Subsequent treatment with CER-001 injected into the vitreous body showed a statistical reduction in signs of uveitis, as measured by protein concentration and cellular infiltration into aqueous humor.

These first preclinical results indicate the major therapeutic potential of bio-HDL in ophthalmology, and more broadly the role of lipids in ocular pathologies.

Dr Christophe Baudouin, professor of ophthalmology in Paris, head of the ophthalmology department at the National Hospital of Ophthalmology of the Quinze-Vingts Hospital (Paris), director of the “S12” research team at the Institut de la Vision , and member of the prestigious international societies, American Society of Ophthalmology and Academia Ophthalmologica Internationalis, states: “The latest scientific work in the field shows that lipids and their metabolism are involved in many eye pathologies, for example meibomian gland dysfunction and macular degeneration. By testing CER-001, a biomimetic HDL produced in France, in models of ocular pathology, we will be able to help choose the best ocular indication for this product, with the aim of offering patients a new effective treatment. “

Development of the first class of biomedicines in ophthalmology with bio-HDL

Following the obtaining of the orphan designation by the European Medicines Agency (EMA) for its drug candidate CER-001 as a potential treatment for LCAT deficiency, ABIONYX Pharma’s bio-HDL is one of the most popular biomedicines. more advanced in France which could soon be marketed in ophthalmology.

As a reminder, there are two forms of LCAT deficiency:

– familial LCAT deficiency (FLD), which results from a complete deficiency and is clinically characterized by hemolytic anemia, renal failure (frequently leading to renal transplantation) and corneal opacities; and

– “Fish Eye Disease” resulting from a partial deficiency and clinically characterized by more severe corneal opacities without renal damage.

As the orphan drug designation obtained covers both a renal indication and an ophthalmologic indication, the clinical development of bio-HDL in ophthalmology can be very rapid.

Lipids are of major interest to the eye in several respects: its structural role, its functional role, its pathophysiological links and its therapeutic potential.

Dr Catherine Creuzot-Garcher, Professor of Ophthalmology in Dijon, Head of the Ophthalmology Department at Dijon University Hospital, University Professor, co-head of the Eye, Nutrition and Cell Signaling team at the Center des Sciences du Goût et de l’Alimentation in Dijon, and Dr Niyazi Acar (PhD), head of the Eye, Nutrition and Cellular Signaling team at the Dijon Center for Taste and Food Sciences, declares: “The study and development of the therapeutic potential of CER-001, a biomimetic HDL, in the treatment of eye diseases will allow us to better understand the role of lipids in the physiology and dysfunctions of the eye, in particular of the retina,” and to offer our patients an innovative solution for the future. “

The anti-inflammatory and / or reverse lipid transport enhancing properties of CER-001, which may improve vision in patients with deficient LCAT activity, combined with new preclinical findings in uveitis, pave the way for studies clinical trials testing bio-HDL in patients developing corneal lipid deposits from other pathologies, and allow ABIONYX Pharma to launch a strategic development of the first class of biomedicines in ophthalmology based on its bio-HDL.

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotechnology company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest. Thanks to its partners in research, medicine, biopharmaceuticals and shareholders, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211006006078/en/

Contacts

NewCap
Investor Relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0) 1 44 71 98 53

NewCap
Media relations
Nicolas merigeau
abionyx@newcap.eu
+33 (0) 1 44 71 94 98

Source link

]]>
https://vetclinpathjournal.org/abionyx-pharma-announces-positive-preclinical-results-in-a-uveitis-model-and-launches-the-strategic-development-of-the-first-class-of-biomedicines-in-ophthalmology-based-on-its-bio-hdl/feed/ 0
Tiny bubbles promise to reduce inflammation https://vetclinpathjournal.org/tiny-bubbles-promise-to-reduce-inflammation/ https://vetclinpathjournal.org/tiny-bubbles-promise-to-reduce-inflammation/#respond Thu, 07 Oct 2021 02:43:00 +0000 https://vetclinpathjournal.org/tiny-bubbles-promise-to-reduce-inflammation/

Scientists are hoping that tiny bags of material excreted by cells – known as extracellular vesicles – can be used to deliver drugs inside the body. Researchers at Karolinska Institutet are now showing that these nanobubbles can carry protein drugs that reduce inflammation caused by different diseases. The technique, which is presented in Nature Biomedical Engineering, shows promising results in animal models.

Extracellular vesicles (EVs) are important in intercellular communication as vectors of biological signals. These are nanoscale membrane-covered packages excreted by cells that can deliver fatty acids, proteins, and genetic material to different tissues.

The tiny bubbles are found naturally in body fluids, are able to cross biological barriers, such as the blood-brain barrier, and can be used as natural carriers of therapeutic substances. Therefore, electric vehicles have gained increasing interest as potential drugs.

Using biomolecular techniques, researchers at Karolinska Institutet coated the outer membrane of the EV with therapeutic proteins, specifically receptors that bind to inflammatory substances TNF-α and interleukin 6 (IL 6).

TNF-α and IL 6 are formed in the body under inflammatory conditions such as multiple sclerosis (MS) and inflammatory bowel disease (IBD), and play a key role in inflammation and resulting tissue damage. This knowledge has led to the development of biological drugs that attenuate the inflammatory response by inhibiting TNF-α and IL 6.

In the present study, the researchers attempted to inhibit inflammatory substances using therapeutic electric vehicles that express receptors on their membranes that bind to IL 6 and TNF-α.

We used different methods to optimize receptor expression and tested different variants of EVs in inflammatory cell models to identify which strategy gave the greatest anti-inflammatory effect. “

Dhanu Gupta, PhD student, Department of Laboratory Medicine, Karolinska Institutet

Dhanu Gupta is the first joint author of the study with his colleague in the department Oscar Wiklander.

The researchers then examined the effects of therapeutic electric vehicles in three inflammatory animal models relevant to sepsis (blood poisoning), MS and IBD.

In the animal model of sepsis, treatment significantly improved survival, suggesting successful damping of the inflammatory response.

In the MS model, researchers also found a significant reduction in the neurological symptoms seen during MS flares. Treatment with electric vehicles expressing both receptors also showed a significant increase in survival in mouse models of IBD.

“Our results are an important step in the right direction and demonstrate that electric vehicles can be a promising treatment for inflammation, but the technique also has great potential for many other diseases,” says Samir EL Andaloussi, principal investigator at Department of Laboratory Medicine, Karolinska Institutet and co-last author of the study with Joel Nordin from the same department.

Source:

Journal reference:

Gupta, D., et al. (2021) Improvement of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nature Biomedical Engineering. doi.org/10.1038/s41551-021-00792-z.

Source link

]]>
https://vetclinpathjournal.org/tiny-bubbles-promise-to-reduce-inflammation/feed/ 0
Area pets await care as vets tackle backlogs and staff shortages https://vetclinpathjournal.org/area-pets-await-care-as-vets-tackle-backlogs-and-staff-shortages/ https://vetclinpathjournal.org/area-pets-await-care-as-vets-tackle-backlogs-and-staff-shortages/#respond Thu, 07 Oct 2021 01:01:24 +0000 https://vetclinpathjournal.org/area-pets-await-care-as-vets-tackle-backlogs-and-staff-shortages/

ONALASKA, Wisconsin (WKBT) – The average number of vet appointments increased 4.5% between 2019 and 2021, according to the American Veterinary Medical Association.

The La Crosse region reflects the fact that many of these nominations are overdue. At the start of the pandemic, veterinary care providers were declared essential, but only for urgent appointments.

“We postponed welfare care for a few months on a group of pets, which created a significant backlog that you have to catch up with at some point,” said Dr Douglas Kratt, veterinarian at Central Animal. Hospital d’Onalaska.

As things opened up, more and more services became available again. But Kratt found that besides the backlog, his clinic couldn’t function as efficiently as it used to.

“Before the pandemic, we would frequently be able to have people in the same week. Sometimes the same day, but the same week. Now there are times when we book two to three weeks, ”Kratt said.

Throughout the pandemic, people adopted pets that needed care that they did not have immediate access to.

“It is the adoption exams and the exams of the new puppy, kitten, that are really very, very important, so we can talk about proper nutrition and proper care for these pets to try and avoid the care. urgent, potentially, ”Kratt said.

Although new pets were adopted, the main cause of the influx of dates was time spent at home.

“A lot of people then spend more time with their pets, so they would see more things that could be a problem. There could be more lameness, there could be this new bump, ”Kratt said.

Beyond the influx of patients, veterinary surgeries are also facing a labor shortage. Central Animal Hospital is short of five employees.

“The stressors on the veterinary community, like really almost any industry – it’s not a new phenomenon. I think it’s worsened because of COVID,” Kratt said.

It is a space that Kratt hopes to be able to fill soon. Although the AVMA reports that COVID-19 precautions have limited the productivity and efficiency of the team. Kratt says that implementing telehealth visits to his clinic has helped fill some of these gaps.

Kratt says he advises clients to schedule pet appointments long before they’re needed to make sure these issues are caught before they arise.

Recent news from News 8 Now

‘It was an incredible challenge’: Problems in the food supply chain put Holmen and Western meal programs to the test

Kwik Trip Glazers makes last 4 in Wisconsin’s coolest things contest
Coulee Recovery Center hosting the “Operation Deal and Heal” program for veterans
Trempealeau County Highway 35 crashes raise concerns among business owners

]]> https://vetclinpathjournal.org/area-pets-await-care-as-vets-tackle-backlogs-and-staff-shortages/feed/ 0